Auxilium Pharmaceuticals (AUXL) Reports Preliminary Fourth Quarter 2010 Net Revenue

MALVERN, Pa., Jan. 10, 2011 /PRNewswire/ — Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today reported that preliminary fourth quarter 2010 total net revenue was $61.8 million, up 28.7% compared with $48.0 million in the fourth quarter of 2009.  For the full year 2010, preliminary total net revenue was $211.4 million, up 28.9% compared with $164.0 million in 2009.

(Logo:  http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

“We are energized by the significant progress that Auxilium made in 2010. We achieved record revenues for Testim®, launched XIAFLEX® in the U.S. for Dupuytren’s contracture, received a positive CHMP opinion with our EU partner, Pfizer, for XIAFLEX for Dupuytren’s contracture, and initiated XIAFLEX global phase III clinical trials for Peyronie’s disease,” said Armando Anido, Chief Executive Officer and President of Auxilium.  “As we look forward to 2011 and beyond, we expect Testim revenues to continue to grow and believe that the potential global market for XIAFLEX represents a blockbuster opportunity, which could provide sustainable long-term growth for the Company.”

Preliminary Fourth Quarter 2010 Revenue Details

Auxilium reported the following unaudited net revenues (all amounts in millions of dollars) for the quarter ended December 31, 2010:

Contract Revenues represent amortization of previously received upfront and milestone payments.

Preliminary 2010 Revenue Details

Auxilium reported the following unaudited net revenues (all amounts in millions of dollars) for the full year 2010:

Contract Revenues represent amortization of previously received upfront and milestone payments.

2011 XIAFLEX Net Revenue Guidance

For 2011, Auxilium anticipates that 2011 XIAFLEX net revenues will be in the range of $55.0 to $67.0 million, including approximately $50.0 to 60.0 million in U.S. revenue, and $5.0 to 7.0 million in revenue recognized from royalties and milestones under the Pfizer contract.

Upcoming Investor Presentation

Auxilium reported these numbers in advance of a presentation to investors tomorrow, January 11, 2011 at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, when Auxilium’s Chief Executive Officer and President, Armando Anido, will outline the Company’s strategic priorities.

Mr. Anido will speak at 4:00 p.m. PT (7:00 p.m. ET) tomorrow, and his remarks will be webcast via a link on the “For Investors” section of www.auxilium.com. Mr. Anido will give an overview of the Auxilium current business strategy, which will focus on the following areas:

• maximizing the value of Testim and XIAFLEX,
• delivering on the current pipeline,
• building out the pipeline in specialty therapeutic areas.

A PDF of the presentation slides to be used during the remarks is now available on the “For Investors” section of the Auxilium web site under the “Presentations” tab.  A question and answer session will follow tomorrow’s presentation and will also be webcast.  The presentation webcast, the presentation slides and the question and answer session webcast can be accessed via a link on the “For Investors” section of the Auxilium web site under the “Events” tab.  The replay will be available for ninety days after the event.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists.  Auxilium markets XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren’s contracture patients with a palpable cord and Testim® 1%, a topical testosterone gel, for the treatment of hypogonadism.  Auxilium has four projects in clinical development.  XIAFLEX is in phase III of development for the treatment of Peyronie’s disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis).  Auxilium’s transmucosal film product candidate for the treatment of overactive bladder (AA4010) and its fentanyl pain product using its transmucosal delivery system are in phase I of development.  The Company is currently seeking a partner to further develop these product candidates.  Auxilium has rights to additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system.  Auxilium also has options to all indications using XIAFLEX for non-topical formulations.  For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release contains “forward-looking-statements” within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s intention to present at the 29th Annual J.P. Morgan Healthcare Conference; anticipated net revenues for 2011; and products in development for Peyronie’s disease, Frozen Shoulder syndrome, overactive bladder, pain, hormone replacement and urologic disease; and all other statements containing projections, statements of future performance or expectations, our beliefs or statements of plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Forward-looking statements can generally be identified by words such as “believe,” “appears,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” and other words and terms of similar meaning in connection with any discussion of projections, future performance or expectations, beliefs, plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium’s Annual Report under the heading “Risk Factors” on Form 10-K for the year ended December 31, 2009 and in Auxilium’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, which are on file with the Securities and Exchange Commission (the “SEC”) and may be accessed electronically by means of the SEC’s home page on the Internet at http://www.sec.gov or by means of Auxilium’s home page on the Internet at http://www.Auxilium.com under the heading “For Investors — SEC Filings.” There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium’s expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium’s assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium’s assessments as of any date subsequent to the date of this release.

MAKO Surgical Corp. (MAKO) Reports Selected Operating Results for the Fourth Quarter 2010

FORT LAUDERDALE, Fla., Jan. 10, 2011 (GLOBE NEWSWIRE) — MAKO Surgical Corp. (Nasdaq:MAKO), a medical device company that markets both its RIO® Robotic Arm Interactive Orthopedic surgical platform and proprietary RESTORIS® implants for minimally invasive orthopedic procedures known as MAKOplasty®, today announced its selected operating results for its fourth quarter ended December 31, 2010 in anticipation of its business update presentation at the 29th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 12, 2011 at 2:30 pm PST.

MAKO will provide a live webcast of the business update presentation. Interested parties may access the live webcast by visiting the investor relations section of MAKO’s web site at www.makosurgical.com. A replay of the webcast will be available at the site after the live presentation.

2010 Fourth Quarter and Full Year Review

RIO Systems – Thirteen RIO systems were installed and customer accepted at commercial sites during the fourth quarter. A total of 33 new RIO systems were sold worldwide in 2010 and MAKO’s domestic commercial installed base of RIO systems totaled 67 as of December 31, 2010.

MAKOplasty Procedure Volume – During the fourth quarter, 1,146 MAKOplasty procedures were performed, of which 1,142 procedures were performed at domestic sites, and our clinical research site in Glasgow, Scotland reported that four procedures were performed at its site. The 1,146 MAKOplasty procedures represent a 41% increase over procedures performed in the third quarter of 2010 and a 104% increase over the fourth quarter of 2009. The average monthly utilization per system was 6.7 procedures during the fourth quarter of 2010, an increase from 5.7 procedures per system per month in the third quarter of 2010 and 6.0 procedures per system per month in the fourth quarter of 2009. The average monthly utilization per system for the year ended December 31, 2010 was 6.4. A total of 3,485 MAKOplasty procedures were performed in 2010 and through December 31, 2010, a total of 5,869 procedures have been performed since the first procedure in June 2006.

“We are pleased that our ongoing focus on execution has continued to produce strong operating results,” said Maurice R. Ferre, M.D., President and Chief Executive Officer of MAKO. “We are also pleased that we continue to experience strong adoption of MAKOplasty by surgeons and hospitals.”

Earnings Call Information

MAKO will host a conference call on Tuesday, March 1 at 4:30 pm EST to discuss its fourth quarter and full year 2010 financial results. To listen to the conference call, please dial 877-843-0414 for domestic callers and 914-495-8580 for international callers approximately ten minutes prior to the start time. To access the live audio broadcast or the subsequent archived recording, visit the Investor Relations section of MAKO’s website at www.makosurgical.com.

About MAKO Surgical Corp.

MAKO Surgical Corp. is a medical device company that markets both its RIO® Robotic Arm Interactive Orthopedic system and its proprietary RESTORIS® knee implants for a minimally invasive orthopedic procedure called knee MAKOplasty®. The MAKO RIO is a surgeon-interactive tactile surgical platform that incorporates a robotic arm and patient-specific visualization technology, and prepares the knee joint for the insertion and alignment of MAKO’s resurfacing RESTORIS implants through a minimal incision. The FDA-cleared and CE Marked RIO system allows surgeons to provide precise, consistently reproducible tissue-sparing, bone resurfacing for a large, yet underserved, patient population suffering from early to mid-stage osteoarthritic knee disease. MAKO has an intellectual property portfolio of more than 250 owned or licensed patents and patent applications relating to the areas of robotics, haptics, computer assisted surgery and implants. Additional information can be found at www.makosurgical.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding, among other things, statements related to expectations, goals, plans, objectives and future events. MAKO intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Reform Act of 1995. In some cases, forward-looking statements can be identified by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause actual results to differ materially from those indicated by forward-looking statements, many of which are beyond MAKO’s ability to control or predict. Such factors, among others, may have a material adverse effect on MAKO’s business, financial condition and results of operations and may include the potentially significant impact of a continued economic downturn or delayed economic recovery on the ability of MAKO’s customers to secure adequate funding, including access to credit, for the purchase of MAKO’s products or cause MAKO’s customers to delay a purchasing decision, changes in competitive conditions and prices in MAKO’s markets, unanticipated issues relating to intended product launches, decreases in sales of MAKO’s principal product lines, increases in expenditures related to increased or changing governmental regulation or taxation of MAKO’s business, unanticipated issues in securing regulatory clearance or approvals for new products or upgrades or changes to MAKO’s current products, the impact of the recently enacted United States healthcare reform legislation on hospital spending, reimbursement, and the taxing of medical device companies, loss of key management and other personnel or inability to attract such management and other personnel and unanticipated intellectual property expenditures required to develop, market, and defend MAKO’s products. These and other risks are described in greater detail under Item 1A, “Risk Factors,” in MAKO’s annual report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on March 10, 2010, MAKO’s quarterly report on Form 10-Q for the quarter ended March 31, 2010 filed with the Securities and Exchange Commission on May 7, 2010 and MAKO’s quarterly report on Form 10-Q for the quarter ended September 30, 2010 filed with the Securities and Exchange Commission on November 3, 2010. Given these uncertainties, undue reliance should not be placed on these forward-looking statements. MAKO does not undertake any obligation to release any revisions to these forward-looking statements publicly to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

“MAKOplasty®,” “RESTORIS®,” “RIO®,” as well as the “MAKO” logo, whether standing alone or in connection with the words “MAKO Surgical Corp.” are trademarks of MAKO Surgical Corp.

CONTACT: Investors:
         MAKO Surgical Corp.
         Susan M. Verde
         954-927-2044 x349
         sverde@makosurgical.com

         Westwicke Partners
         Mark Klausner
         443-213-0500
         makosurgical@westwicke.com

Dot Hill (HILL) Expected to Exceed Guidance for Fourth Quarter of 2010

LONGMONT, Colo., Jan. 10, 2011 /PRNewswire/ — Dot Hill Systems Corp. (Nasdaq: HILL), a provider of world-class storage solutions and software for OEMs, open storage partners and system integrators, announced today that it expects to report net revenue, gross margin and earnings per share results for the quarter ended December 31, 2010 to exceed the guidance provided by the company on November 3, 2010.

Based upon preliminary results for the fourth quarter of 2010, the company expects to report:

Net revenue in the range of $65.0 to $65.5 million, compared to previous guidance of $58.0 to $62.0 million.
Non-GAAP* gross margin to be in the range of 21% to 22%, compared to previous guidance of 19% to 20%.
Non-GAAP* earnings per share in the range of $0.02 to $0.04 on a fully diluted basis, compared to previous guidance of a range of a loss of $0.03 to a profit of $0.01.
Cash and cash equivalents are expected to be approximately $45.7 million, up from $41.8 million at the end of the third quarter of 2010.
Management still expects non-GAAP* operating expenses for the fourth quarter of 2010 to be within the guidance range of $12.0 to $12.5 million established on November 3, 2010.

The company attributes the expected net revenue results to strength across all geographies and sales channels in spite of its intentional early termination of its NetApp agreement, effective December 1, 2010.

“I am pleased with the progress we have made in the fourth quarter of 2010,” commented Dana Kammersgard, the company’s president and chief executive officer. “These projected results represent another proof point that our strategy to expand gross margin and create a sustainably profitable business model is on track.”

Hanif Jamal, the company’s senior vice president and chief financial officer stated, “We are encouraged by our preliminary financial results for the fourth quarter of 2010. With respect to the first quarter of 2011, we continue to maintain the same outlook that we provided at the third quarter of 2010 earnings call and anticipate a decline in net revenues due to seasonal factors and the termination of our relationship with NetApp and currently project non-GAAP earnings per share to be at or around a break-even level.”

Dot Hill is still awaiting the completion of the audit of its 2010 financial results and anticipates that it will release final results and first quarter 2011 guidance on its regularly scheduled conference call which is expected to take place in the first half of March 2011.

* About Non-GAAP Financial Measures

This press release contains expected financial results that exclude the effects of stock-based compensation expense, severance costs, restructuring costs, intangible asset amortization, transaction expenses associated with the Company’s acquisition of Cloverleaf, a contingent consideration adjustment and foreign currency gains or losses, and are not in accordance with U.S. generally accepted accounting principles (GAAP). The Company believes that these non-GAAP financial measures provide meaningful supplemental information to both management and investors that is indicative of the Company’s core operating results and facilitates comparison of operating results across reporting periods. The Company uses these non-GAAP measures when evaluating its financial results as well as for internal resource management, planning and forecasting purposes. These non-GAAP measures should not be viewed in isolation from or as a substitute for the Company’s financial results in accordance with GAAP.

About Dot Hill

Delivering innovative technology and global support, Dot Hill empowers the OEM community to bring unique storage solutions to market, quickly, easily and cost-effectively. Offering high performance and industry-leading uptime, Dot Hill’s RAID technology is the foundation for best-in-class storage solutions offering enterprise-class security, availability and data protection. The Company’s products are in use today by the world’s leading service and equipment providers, common carriers and advanced technology and telecommunications companies, as well as government agencies. Dot Hill solutions are certified to meet rigorous industry standards and military specifications, as well as RoHS and WEEE international environmental standards. Headquartered in Longmont, Colorado, Dot Hill has offices and/or representatives in China, Germany, Japan, United Kingdom, Singapore, Israel and the United States. For more information, visit us at http://www.dothill.com.

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include statements regarding Dot Hill’s projected final fourth quarter 2010 and future financial results, financing activities, and Dot Hill’s prospects and maintaining the achievement of profitability. The risks that contribute to the uncertain nature of these statements include, among other things: the risk that actual, audited fourth quarter 2010 financial results will be different from those projected, that Dot Hill’s next-generation products may not achieve market acceptance; the Company’s expense reduction and resource allocation plans may not continue to have the anticipated positive effects on the Company’s financial results; the risks associated with macroeconomic factors that are outside of Dot Hill’s control; the fact that no Dot Hill customer agreements provide for mandatory minimum purchase requirements; the risk that one or more of Dot Hill’s OEM or other customers may cancel or reduce orders, not order as forecasted or terminate their agreements with Dot Hill; the risk that Dot Hill’s new products may not prove to be popular; the risk that one or more of Dot Hill’s suppliers or subcontractors may fail to perform or may terminate their agreements with Dot Hill; unforeseen technological, intellectual property, personnel or engineering issues; and the additional risks set forth in the Forms 10-K and 10-Q most recently filed with the Securities and Exchange Commission by Dot Hill. All forward-looking statements contained in this press release speak only as of the date on which they were made. Dot Hill undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

HILL-F

Hanif Jamal

Chief Financial Officer

Tel: 303-845-3200

Email: investors@dothill.com

Peter Seltzberg

Hayden IR

Tel: 646-415-8972

Email: peter@haydenir.com

ACADIA Pharmaceuticals (ACAD) Announces $15 Million Private Placement

Jan. 10, 2011 (Business Wire) — ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has entered into a securities purchase agreement for a private placement financing with a select group of institutional investors, including New Enterprise Associates and Venrock. Upon the closing of the transaction, ACADIA will receive gross proceeds of $15.0 million from the sale of approximately 12.57 million units at a price of $1.19375 per unit. Each unit consists of one share of ACADIA’s common stock and a warrant to purchase 0.35 shares of common stock. The private placement is expected to close on January 12, 2011 and is subject to the satisfaction of customary closing conditions.

The anticipated proceeds from the private placement will provide ACADIA with additional resources to advance its Phase III pimavanserin program, including the ongoing Phase III trials in Parkinson’s disease psychosis, and is expected to extend ACADIA’s cash runway into 2013.

JMP Securities LLC acted as lead placement agent and MTS Securities, LLC, an affiliate of MTS Health Partners, acted as co-placement agent in the transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. ACADIA has agreed to file a registration statement with the SEC covering the resale of the shares of common stock, including the shares of common stock issuable upon exercise of the warrants, sold in the private placement.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA has a portfolio of four product candidates including pimavanserin, which is in Phase III clinical development as a treatment for Parkinson’s disease psychosis. ACADIA also has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. All of the product candidates in ACADIA’s pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA maintains a website at www.acadia-pharm.com to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.

Forward-Looking Statements

This press release contains statements that are forward-looking, including statements regarding ACADIA’s expectations regarding the amount and expected uses of the proceeds that will be received in the private placement, the length of ACADIA’s cash runway, the expected closing date of the private placement transaction, and the anticipated filing of a registration statement to cover the resale of the shares and warrant shares underlying the warrants expected to be sold in the private placement. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties associated with ACADIA’s ability to complete the private placement and register the shares of common stock, including events outside of ACADIA’s control, as well as the risks and uncertainties inherent in drug discovery and development, including those related to clinical trials. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2009 as well as other subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

ACADIA Pharmaceuticals Inc.

Thomas H. Aasen, 858-558-2871

Executive Vice President, Chief Financial Officer and Chief Business Officer

Subaye, Inc. (SBAY) is “One to Watch”

Subaye, Inc., a leading online business services provider in China, is primarily focused on enterprise cloud computing and video marketing business solutions. The company’s online business services include business to consumer (B2C) ecommerce, e-managment solutions, e-marketing solutions, e-service solutions and video search engine optimization.

Cloud computing is poised to change the way enterprise computing is conducted in China. CCW Research anticipates the Chinese cloud computing market will reach approximately $9 billion (61.3 billion RMB) by 2013. Because few domestic firms have ventured into cloud computing and global firms are less visible in the Chinese market, Subaye has a unique advantage on which to capitalize.

The company began its expansion initiative outside of Guangdong Province in 2010 and will continue to seek out customers of all sizes, primarily through its direct sales force. Subaye recently completed an aggressive expansion of its internal sales force and plans to further increase its sales department to meet the demands of the various markets in China that it now operates in.

The company currently serves its customers from data center hosting facilities located in Guangzhou City, Guangdong Province, China. Subaye plans to add additional data centers in other primary market locations this year while reaching out to potential new customers in new markets, developing and strengthening its local contacts within each market and increasing brand awareness throughout China.

Let us hear your thoughts below:

China Armco Metals’ (CNAM) Recycling Facility Returns to Full Time Operations

Adeona (AEN) to Present at OneMedForum San Francisco 2011 Conference

Amarin (AMRN) Prices Public Offering of American Depositary Shares

Hauppauge (HAUP) Launches Colossus High Definition H.264 Video Recorder for PCs

Jan. 6, 2011 (Business Wire) — 2011 International CES, Booth C9542: Hauppauge Digital, Inc. (NASDAQ: HAUP), the world’s leading developer and manufacturer of TV tuner products for personal computers, today launched its new Colossus internal PCI Express board capable of recording component video and unencrypted HDMI video at up to 1080i from sources such as the Xbox360 and digital SLR cameras.

The latest addition to Hauppauge’s line of high definition video recorders, Colossus is similar to the company’s HD PVR external USB-based H.264 recorder, but offers expanded capability to include HD video recording from the HDMI port on the Xbox360 game console. When connected to an Xbox360, an HDMI cable can be used to record game play at video resolutions up to 1080i. When connected to a Playstation3, game play is recorded using component video at 1080i resolution.

Colossus allows users to make high definition video recordings of their highest-score games and even game tutorials, directly from the game console. Users can record game play in HD and then upload the recording to YouTube or other popular game recording websites. Colossus features pass-through support for component video and digital audio, enabling users to monitor game play on an HD TV set while recording.

When connected to a cable TV or satellite set top box, Colossus users can record TV programs in HD. Colossus includes an IR blaster and the latest WinTV v7 application so that users can schedule a recording and have the Colossus “blast” channel commands to the set top box at the appropriate time.

With Colossus connected to a set top box, a user can record a TV show or a complete TV series in high definition to their PCs hard disk, make HD libraries of favourite TV programs and then playback to the PC screen or burn the recording onto a disk in a high definition Blu-ray™ format.

Colossus is supplied with two applications: the Hauppauge WinTV v7 application for scheduled recording of TV programs from cable TV and satellite set top boxes, and Arcsoft’s ShowBiz, which allows users to record from a game console, trim the beginning and end of video recordings and immediately upload the recordings to YouTube. ShowBiz makes recording video game play and uploading to YouTube with Colossus easy.

SageTV, a software company based in Inglewood, California, has announced support for Colossus in their Windows-based digital video application, SageTV 7.x. SageTV is a popular application providing complete DVR capability on a PC.

Pricing, availability and press pictures

Colossus will have a MSRP of $159 and will be available late January 2011.

Pictures of Colossus can be found here:

http://www.hauppauge.com/site/press/presspictures/colossus_board-cables.png

http://www.hauppauge.com/site/press/press_pictures_hdpvr.html#press_colossus

About Hauppauge

Hauppauge Digital, Inc. (NASDAQ: HAUP) is a leading developer and manufacturer of digital TV and data broadcast receiver products for personal computers. Through its Hauppauge Computer Works, Inc., PCTV Systems Sarl and Hauppauge Digital Europe subsidiaries, the Company designs and develops digital video boards for TV-in-a-window, digital video editing and video conferencing. The Company is headquartered in Hauppauge, New York, with R&D offices in New York, Braunschweig, Germany and Taipei, and administrative offices in New York, Singapore, Taiwan, Ireland and Luxembourg and sales offices in Germany, London, Paris, The Netherlands, Sweden, Italy, Spain, Singapore and California. The Company’s Internet web site can be found at http://www.hauppauge.com. Hauppauge and WinTV are registered trademarks of Hauppauge Computer Works, Inc. Other product or service names herein are the trademarks of their respective owners.

Press Contacts:

Brice Washington

Hauppauge Computer Works

bwashington@hauppauge.com

or

Belinda Rooney

S&S Public Relations

609 750 9110 – office

brooney@sspr.com

Augme Technologies, Inc. (AUGT.OB) is “One to Watch”

Augme Technologies, Inc. offers cutting-edge media marketing platforms that enable the seamless integration of brands, music, video and other content with life through the power of today’s technology. Using Augme Technologies’ intuitive media marketing platforms, companies can quickly create, deploy and measure rich-media, interactive marketing campaigns across all networks and devices.

Augme’s unique services personalize the brand experience by delivering that experience to customers where they work, play and live. Through its three operating divisions, mobile marketing (AD LIFE™), video content delivery (BOOMBOX) and ad network provisioning (AD SERVE™), Augme connects brands and content to consumers in a way that enables companies and their marketing agencies to create new markets and monetize brand interactions.

Augme owns US Patent No. 6,594,691, patent No. 7,269,636, patent No. 7,783,721, and patent No. 7,831,690, which cover a two-code module system that enables any networked, delivered content to be customized based on end-user criteria. These patents cover indispensable distribution and delivery aspects of behavioral targeting advertisements and content delivery over the Internet and related networks and processor platforms. Today’s advanced behavioral targeting would simply not be possible without employing Augme’s intellectual property.

Following an extensive infringement analysis concentrated on the largest players in the business of targeted Web-content delivery, Augme Technology has determined potential infringement by the top six search engine, e-commerce and numerous other companies represent approximately $5 billion in discounted net free cash flow over the life of the patents without any continuations. Augme Technology’s patents are crucial to the facilitation of behavioral targeted ads and content utilized by these organizations.

In a recent press release, Augme Technology forecasted recognizable revenues will exceed $12 million over the next twelve months, based on an estimate that approximately 50% of current bookings will convert into revenues within that time frame. With a solid portfolio of innovative marketing services and the intellectual property in place to protect those services, the company is well positioned for further growth as the market for behavior based advertising continues to grow.

Let us hear your thoughts below:

Cereplast (CERP) Opens Nationwide “Make Your Mark” Competition for New Bioplastics Symbol

Jan. 3, 2011 (Business Wire) — Cereplast, Inc. (NASDAQ: CERP), a leading manufacturer of proprietary bio-based, compostable and sustainable plastics, announced today that it has opened its nationwide design competition, “Make Your Mark,” for a symbol that represents “bioplastics.” The symbol will indicate that a product is made from “green,” bio-based material, not petroleum-based material. “Make Your Mark” design entries can be submitted via www.iizuu.com/cereplast, where the official rules and guidelines are also posted. Visit the “About” tab for additional contest details and the “Contest” tab to vote for or to submit a design.

“Cereplast’s competition represents our commitment to educating and helping consumers make smarter purchasing decisions that help preserve and protect our environment,” said Frederic Scheer, Chairman and CEO of Cereplast. “Companies are increasingly looking at bio-based plastics made from renewable resources like corn, wheat, and algae as an alternative to petroleum-sourced plastics in order to meet soaring consumer demand for economically and ecologically sound, ‘green’ products. The bioplastics symbol will enable consumers to easily identify products made from bioplastics, similar to the globally recognized recycling symbol we see on thousands of plastic products.”

The Make Your Mark bioplastics symbol contest is open to legal residents of the United States. Entrants are required to submit a symbol design that, when stamped on a product, will clearly serve as an indication that the product is made from bioplastics. This new symbol will serve in a similar fashion to how the recycling symbol is used to identify products that are made from recycled materials and/or are recyclable.

It is mandatory for the design to have the ability to be “single-color,” or colorless, and easily identifiable. Design submissions need to include three variations to symbolize the end of life options for the product—whether to compost or recycle it. The three variations include: a general bioplastics symbol; a version identifying compostability; and a version indicating recyclability.

The deadline for Make Your Mark design entries is March 4, 2011. The top 50 entries will be determined based on a public voting system available at www.iizuu.com/cereplast. The judges will select the top three designs and the winner will be announced on Earth Day Eve, April 21, 2011, at a gala event in Los Angeles, California, in honor of the internationally celebrated Earth Day. The designer of the winning bioplastics symbol will receive $25,000.

Forty-one years ago, Gary Anderson won the competition that produced the globally recognized recycling symbol we see on recycled and recyclable products today. Mr. Anderson and industrial designer Karim Rashid are among the panel of renowned judges.

Cereplast produces bio-based, compostable and sustainable plastic substitutes that serve as an environmentally safer alternative to petroleum-based plastics. Cereplast creates a wide range of bioplastic resins to meet surging consumer and industrial demand for economically and ecologically sound, “green” products. Made from renewable resources, — corn, wheat, tapioca, potatoes and algae — Cereplast bioplastics replace traditional petroleum-based plastics in the manufacturing of products and packaging.

About Cereplast, Inc.

Cereplast, Inc. (NASDAQ: CERP) designs and manufactures proprietary bio-based, sustainable plastics which are used as substitutes for petroleum-based plastics in all major converting processes – such as injection molding, thermoforming, blow molding and extrusions – at a pricing structure that is competitive with petroleum-based plastics. On the cutting-edge of bio-based plastic material development, Cereplast now offers resins to meet a variety of customer demands. Cereplast Compostables® Resins are ideally suited for single use applications where high bio-based content and compostability are advantageous, especially in the food service industry. Cereplast Sustainables™ Resins combine high bio-based content with the durability and endurance of traditional plastic, making them ideal for applications in industries such as automotive, consumer electronics and packaging. Learn more at www.cereplast.com. You may also visit the Cereplast social networking pages at Facebook.com/Cereplast, Twitter.com/Cereplast and Youtube.com/Cereplastinc.

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

Cereplast, Inc.

Nicole Cardi

310-615-1900 x154

ncardi@cereplast.com

or

MKR Group, Inc.

Investor Relations

Charles Messman or Todd Kehrli

323-468-2300

cerp@mkr-group.com

or

Trontz Public Relations

Bari Trontz

212-566-2310

bari@trontzpr.com

OCZ Technology (OCZ) to Extend Enterprise Solid State Drive Reach at Storage Visions 2011 Conference

SAN JOSE, Calif., Jan. 3, 2011 (GLOBE NEWSWIRE) — OCZ Technology Group, Inc. (Nasdaq:OCZ), a leading provider of high-performance solid-state drives (SSDs) and memory modules for computing devices and systems, will be exhibiting at the 2011 Storage Visions Conference in Las Vegas, Nevada January 4-5 at the Riviera Convention Center.

“Storage Visions represents a great opportunity to meet face to face with customers and key partners within the fast evolving storage space,” said Alex Mei, CMO of OCZ Technology. “At the conference we will be displaying an array of our customizable Deneva enterprise solid state drive products as well as next generation PCIe solutions, and we look forward to exploring the latest storage technology and trends with attendees at this highly targeted event.”

OCZ enterprise SSD products help overcome the performance, durability, and maintenance obstacles inherent to traditional mechanical HDD storage. In addition to the superior design, reliability, and speed, OCZ’s ability to provide a custom solution ensures ultimate compatibility, reliability and cost savings that other SSD lines cannot deliver. Furthermore, Deneva solutions provide superior performance by delivering up to 50,000 IOPS and 285MB/s of bandwidth, and feature world-class reliability features including superior power loss protection, endurance, encryption, and ECC protection in a wide variety of interfaces.

Join OCZ Technology Group at Storage Visions as the Company highlights new solutions designed to increase the advantages of SSDs over traditional hard disc drives for OEMs and enterprise clients who place a premium on performance, reliability, and superior total cost of ownership (TCO).

About OCZ Technology Group, Inc.

Founded in 2002, San Jose, CA-based OCZ Technology Group, Inc. (“OCZ”) is a leader in the design, manufacturing, and distribution of high performance and reliable Solid-State Drives (SSDs) and premium computer components. OCZ has built on its expertise in high-speed memory to become a leader in the SSD market, a technology that competes with traditional rotating magnetic hard disk drives (HDDs). SSDs are faster, more reliable, generate less heat and use significantly less power than the HDDs used in the majority of computers today. In addition to SSD technology, OCZ also offers high performance components for computing devices and systems, including enterprise-class power management products as well as leading-edge computer gaming solutions. For more information, please visit: www.ocztechnology.com.

The OCZ Technology Group, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7439

Forward-Looking Statements Certain statements in this release relate to future events and expectations and as such constitute forward-looking statements involving known and unknown factors that may cause actual results of OCZ Technology Group, Inc. to be different from those expressed or implied in the forward-looking statements. In this context, words such as “will,” “would,” “expect,” “anticipate,” “should” or other similar words and phrases often identify forward-looking statements made on behalf of OCZ. It is important to note that actual results of OCZ may differ materially from those described or implied in such forward-looking statements based on a number of factors and uncertainties, including, but not limited to, market acceptance of OCZ’s products and OCZ’s ability to continually develop enhanced products; adverse changes both in the general macro-economic environment as well as in the industries OCZ serves, including computer manufacturing, traditional and online retailers, information storage, internet search and content providers and computer system integrators; OCZ’s ability to efficiently manage material and inventory, including integrated circuit chip costs and freight costs; and OCZ’s ability to generate cash from operations, secure external funding for its operations and manage its liquidity needs. Other general economic, business and financing conditions and factors are described in more detail in “Item 1A — Risk Factors” in Part II in OCZ’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2010. The filing is available both at www.sec.gov as well as via OCZ’s website at www.ocztechnology.com. OCZ does not undertake to update its forward-looking statements.

CONTACT: OCZ Technology Group, Inc.
         Bonnie Mott, Investor Relations Manager
         408-733-8400

Gasco Energy (GSC) Completes Planned Succession

Dynatronics (DYNT) Named Contract Supplier to Premier, Inc.

BioTime Subsidiary ReCyte Therapeutics, Inc. to Develop Therapies for Age-Related Cardiovascular and Blood Disorders

Jan. 3, 2011 (Business Wire) — BioTime, Inc. (NYSE Amex:BTX) today announced a $4 million equity financing by its subsidiary, Embryome Sciences, Inc. Concurrent with the financing, Embryome Sciences will be renamed ReCyte Therapeutics, Inc. and will develop therapeutic products for cardiovascular and blood diseases. The new equity financing is being led by a $2.5 million investment by private investors and a $1.5 million investment from BioTime that valued ReCyte Therapeutics at a post money valuation of $60 million on a fully diluted basis. ReCyte Therapeutics has also adopted a 4,000,000 share stock option plan for officers, directors, key employees, and key consultants. Following the transaction, BioTime will retain an ownership interest of approximately 95.15% of the outstanding shares of ReCyte Therapeutics.

BioTime expects to consolidate the research product business previously conducted through Embryome Sciences with the research products business conducted by BioTime’s subsidiary ES Cell International Pte Ltd. which already markets other research products such as human embryonic stem cell lines produced under GMP- compliant conditions.

The National Academy of Sciences has estimated that a potential 58 million Americans afflicted with cardiovascular disease and 30 million with autoimmune disorders could potentially benefit from stem cell-based therapies. Combined, this 88 million US target population is one of the largest and fastest growing markets due to the aging of the baby boom population. ReCyte Therapeutics will directly target these markets by utilizing its ReCyte^™ technology to reverse the developmental aging of human cells, then to generate embryonic vascular and blood progenitors from the ReCyte cell lines for therapeutic use in age-related vascular and blood disorders such as coronary disease and heart failure. In 2011, ReCyte Therapeutics intends to begin to build a near-term revenue business by offering a service to reverse the developmental aging of human cells, and to generate blood and vascular progenitors, for cell banking purposes. Neither service in the cell banking business is expected to require lengthy FDA approval. With the capital obtained from the current equity financing, ReCyte Therapeutics will also begin preclinical studies to support future clinical trials of this new class of human therapeutics for vascular and blood disorders. These latter therapeutic uses of the cells will require testing and approval by regulatory agencies such as the FDA.

Background:

Human embryonic stem (hES) cells have the potential to generate all human cell types. Because they are isolated at the earliest stages of the development of human life, the clock of cellular aging located in the telomeric region of DNA is set at a youthful state through the activity of the enzyme telomerase. iPS cells are an alternative technology that begins with adult body cells, such as skin cells, that are modified such that they have the powerful properties of hES cells to become any cell type in the body. iPS cells have the advantages that they can be produced from a patient’s own cells in order to prevent transplant rejection. In addition, since iPS cells never involve the use of embryos, they obviate the ethical concerns voiced by some people in regard to the use of hES cells.

On March 16, 2010 BioTime and its collaborators announced the publication of a scientific paper titled “Spontaneous Reversal of Developmental Aging in Normal Human Cells Following Transcriptional Reprogramming.” The article, which was released online in the peer-reviewed journal Regenerative Medicine demonstrated that the aging of human cells can be reversed with potentially significant implications for the development of new classes of iPS cell-based therapies targeting age-related degenerative disease. The on-line version of the article can be found at http://www.futuremedicine.com/doi/abs/10.2217/rme.10.21.

In the article, BioTime and its collaborators demonstrated the successful reversal of the developmental aging of normal human cells. Using precise genetic modifications, normal human cells were induced to reverse both the “clock” of differentiation (the process by which an embryonic stem cell becomes the many specialized differentiated cell types of the body), and the “clock” of cellular aging (telomere length). As a result, the iPS cells became young pluripotent stem cells with the potential of generating young body cell types that may be transplanted into a patient to replace the patient’s damaged or diseased tissues. ReCyte Therapeutics already has licenses for iPS technology, as well as its own proprietary ReCyte™ iPS technology, that it plans to use in this new field of research.

ReCyte Therapeutics plans to develop a manufacturing process for the large scale reprogramming of human skin cells by resetting telomere length and simultaneously resetting the cell’s stage of development to the embryonic state. The object of this aspect of the research and development will be to build a cost-effective manufacturing platform that will be the basis of a cell banking service planned for launch in 2011.

ReCyte Therapeutics will also develop primitive ReCyte™ cell-derived angioblasts and blood stem cells, which are cells believed to be capable of reconstituting and repairing age-related changes in the vascular and blood systems respectively. The young vascular-forming cells (angioblasts) will be tested in preclinical mouse models of accelerated aging to score their safety and efficacy in restoring blood flow in models of ischemia.

“The vascular system has long been regarded as the leading target of interventional gerontology,” said Michael D. West, Ph.D., President and Chief Executive Officer of BioTime, Inc. and ReCyte Therapeutics. “We anticipate that the first-in-class therapies that ReCyte Therapeutics intends to develop using technology based on telomere and stem cell research, may provide important new modalities for treatment of the largest cause of mortality in the United States.”

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is developed through subsidiaries focused on specific fields of applications. BioTime develops and markets research products in the field of stem cells and regenerative medicine. BioTime’s wholly owned subsidiary ES Cell International (ESI) has produced clinical-grade human embryonic stem cell lines that were derived following principles of Good Manufacturing Practice and currently offers them along with a wide array of ACTCellerate^™ cell lines, culture media, and differentiation kits for use in research. BioTime’s therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime’s majority owned subsidiary Cell Cure Neurosciences, Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. Cell Cure’s minority shareholder Teva Pharmaceutical Industries has an option to clinically develop and commercialize Cell Cure’s OpRegen™ retinal cell product for use in the treatment of age-related macular degeneration (AMD). BioTime’s subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the therapeutic applications of stem cell technology in cancer. ReCyte Therapeutics is developing applications of BioTime’s proprietary iPS cell technology to reverse the developmental aging of human cells for cardiovascular and blood cell aging. In addition to its stem cell products, BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, and technology for use in surgery, emergency trauma treatment and other applications. BioTime’s lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime, ReCyte Therapeutics, Cell Cure, OrthoCyte, OncoCyte, BioTime Asia, and ESI can be found on the web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company’s business, particularly those mentioned in the cautionary statements found in the company’s Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0

BioTime, Inc.

Judith Segall, 510-521-3390, ext. 301

jsegall@biotimemail.com

SI Financial Group, Inc. (SIFI) Announces Approval of Plan of Conversion and Reorganization by Shareholders and MHC Members

WILLIMANTIC, Conn.–(BUSINESS WIRE)–SI Financial Group, Inc. (the “Company”) (Nasdaq: SIFI), holding company for Savings Institute Bank and Trust Company, announced today that the Company’s Plan of Conversion and Reorganization and the related contribution of up to $500,000 in cash to SI Financial Group Foundation, Inc. were each approved by the members of SI Bancorp, MHC and by the Company’s shareholders at separate special meetings held today.

Completion of the conversion remains subject to final regulatory approvals and the sale of a minimum of $44.6 million of common stock.

SI Financial Group, Inc. is the holding company for Savings Institute. Established in 1842, Savings Institute is a community-oriented financial institution headquartered in Willimantic, Connecticut. Through its twenty-one branch locations, Savings Institute offers a full-range of financial services to individuals, businesses and municipalities within its market area.

This press release contains certain forward-looking statements about the conversion and offering. Forward-looking statements include statements regarding anticipated future events and can be identified by the fact that they do not relate strictly to historical or current facts. They often include words such as “believe,” “expect,” “anticipate,” “estimate,” and “intend” or future or conditional verbs such as “will,” “would,” “should,” “could,” or “may.” Forward-looking statements, by their nature, are subject to risks and uncertainties. Certain factors that could cause actual results to differ materially from expected results include delays in consummation of the conversion and offering, difficulties in selling the common stock or in selling the common stock within the expected time frame, increased competitive pressures, changes in the interest rate environment, general economic conditions or conditions within the securities markets, and legislative and regulatory changes that could adversely affect the business in which SI Financial Group and Savings Institute are engaged.

A registration statement relating to these securities has been filed with the United States Securities and Exchange Commission. This press release is neither an offer to sell nor a solicitation of an offer to buy common stock. The offer will be made only by means of the written prospectus forming part of the registration statement (and, in the case of the subscription and community offerings, an accompanying stock order form).

The shares of common stock of new SI Financial Group are not savings accounts or savings deposits, may lose value and are not insured by the Federal Deposit Insurance Corporation or any other government agency.

SI Financial Group, Inc. is the holding company for Savings Institute Bank and Trust Company. Established in 1842, the Savings Institute Bank and Trust Company is a community-oriented financial institution headquartered in Willimantic, Connecticut.

Tri-Valley Corp. (TIV) Exchanges 75% of its Series A and B Warrants for Common Shares

BAKERSFIELD, Calif.–(BUSINESS WIRE)–Tri-Valley Corporation (NYSE Amex:TIV) today announced that it has entered into three separate exchange agreements with three institutional investors for the exchange and cancellation of their Series A, B and C warrants for shares of the Company’s common stock. Under the terms of each of the agreements, the investors exchanged and cancelled warrants to purchase an aggregate of 6,900,975 shares of Tri-Valley’s common stock for an aggregate of 3,975,000 shares of the Company’s common stock. The warrants were issued in a registered direct offering on April 6, 2010.

In addition, each of the investors agreed to cancel the remaining provisions of the Securities Purchase Agreement, including the right of participation of up to 50% in any future financing that expires on April 6, 2011.

“We are very pleased to have substantially reduced the potential dilution of our common shares associated with these warrants as part of our plans to better position Tri-Valley to take advantage of its oil and gas asset base, in a strong commodity price environment. Cancellation of these warrants provides Tri-Valley with much more in the way of financing options, several of which we have been exploring to further the development of oil reserves at our Claflin and Pleasant Valley projects,” said Mr. Maston N. Cunningham, President and CEO of Tri-Valley Corporation.

Approximately 2.1 million Series A and B warrants will remain outstanding after the exchange.

Tri-Valley has applied to the NYSE Amex Exchange to list the Tri-Valley stock to be issued in the exchanges, and closing of the transaction will be subject to NYSE Amex approval of the listing.

Material Terms of the Exchange Agreements

Closing of each transaction is expected to occur on December 31, 2010. Tri-Valley will issue its stock in exchange for the warrants without payment of any additional consideration. After the exchange, the warrants will be canceled.

The exchange agreements contain customary warranties from each investor regarding their organization, authorization to execute the agreements, and their ownership of the warrants at the time of the exchange. Tri-Valley also makes customary warranties to each investor, including with respect to its own organization, authorization and due issuance of the stock being exchanged. Tri-Valley also confirms that it has not provided material, nonpublic information to the investors. Tri-Valley also agrees to file a Current Report on Form 8-K with the SEC as soon as practicable.

Upon completion of the exchange, the securities purchase agreement that Tri-Valley and the investors entered on April 6, 2010, will terminate as to the three exchanging investors. If any agreement is made with respect to an exchange, amendment or exercise of Tri-Valley’s remaining outstanding warrants on terms more favorable than the present exchange agreements within 45 days after closing of the exchange agreements, the investors will be entitled to receive an economic benefit equal to the more favorable terms of the future agreement.

About Tri-Valley

Tri-Valley Corporation explores for and produces oil and natural gas in California, and has two exploration-stage gold properties in Alaska. Tri-Valley is incorporated in Delaware and is publicly traded on the NYSE Amex exchange under the symbol “TIV.” Our Company website, which includes all SEC filings, is www.tri-valleycorp.com.

Forward-looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Actual results, events, and performance could vary materially from those contemplated by these forward-looking statements which include such words and phrases as exploratory, wildcat, prospect, speculates, unproved, prospective, very large, expect, potential, etc. Among the factors that could cause actual results, events, and performance to differ materially are risks and uncertainties discussed in “Item IA. Risk Factors” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, and in “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” as disclosed in the Company’s Quarterly Report on Form 10-Q for the most recent quarter ended September 30, 2010.

Puda Coal (PUDA) Completes Acquisition of Four Coal Mines Under Pinglu Project Phase II

TAIYUAN, China, Dec. 30, 2010 /PRNewswire-Asia-FirstCall/ — Puda Coal, Inc. (NYSE AMEX: PUDA) (“Puda Coal” or the “Company”), a supplier of high grade metallurgical coking coal used to produce coke for steel manufacturing in China and a consolidator of twelve coal mines in Shanxi Province, China, today announced that on December 23 and 24, 2010, Shanxi Puda Coal Group Co. Ltd (“Shanxi Coal”), a 90% subsidiary of Puda Coal, completed acquisition of coal mining rights and assets of four coal mines under Phase II of the Pinglu Project: Pinglu County Sanmenzhen Xuhutuo Coal, Pinglu County Daqi Coal, Shanxi Pinglu Renling Coal and Pinglu County Donggou Coal.

Phase II of the Pinglu Project will be co-developed by Shanxi Coal, Mr. Ming Zhao, Chairman and a principal stockholder of Puda Coal, and Mr. Jianping Gao under a previously announced Investment Cooperation Agreement dated August 1, 2010.  Under the Investment Cooperation Agreement, Shanxi Coal, Mr. Zhao and Mr. Gao will each contribute 40%, 30% and 30%, respectively, of the total investment needed for the consolidation and construction of the coal mines under Pinglu Project Phase II. The parties will share the profits based upon the above investment contribution percentages and bear the risks and losses in connection with the project which will be limited by the amount of investment contributed by each party.

As previously announced by the Company, pursuant to the acquisition agreements, the purchase price is RMB 125,000,000 (approximately $18.77 million) for Xuhutuo Coal, RMB 66,200,000 (approximately $9.94 million) for Daqi Coal,  RMB 205,000,000 (approximately $30.65 million) for Renling Coal and RMB 77,500,000 (approximately $11.59 million) for Donggou Coal. Shanxi Coal paid 50% of the purchase price within three days of execution of each agreement and 40% of the purchase price on December 23 or 24, 2010 after the assets transfers were completed and the mining permits and property deeds were transferred. The remaining 10% of the purchase price will be paid six months after the mining permits and property deeds were transferred.

Shanxi Coal placed all the purchased assets of Xuhutuo Coal and Daqi Coal into a new project company, Shanxi Pinglu Dajinhe Jinmen Coal Co., Ltd. and all the purchased assets of Renling Coal and Donggou Coal into a new project company, Shanxi Pinglu Dajinhe Jinyi Coal Industry Co., Ltd.

“We continue to make significant progress with the acquisition of four of the six coal mines to be consolidated under Phase II of the Pinglu Project. We expect to complete the consolidation and restructuring of these four acquired mines over the next twelve months,” commented Mr. Liping Zhu, President and CEO of Puda Coal, Inc. “Meanwhile, we are advancing our efforts towards applying for construction permits, including safety analysis reports, environmental assessments, preliminary construction and expansion proposals and geological technical reports. We are also in late stage of negotiating with the owners of the two remaining coal mines under Pinglu Project Phase II and expect to enter into acquisition agreements with them in the near term.”

Mr. Zhu added, “We have deployed a team of seasoned professionals and expect to retain key managers from the acquired coal mines to successfully execute the consolidation and restructuring of Pinglu Project. In addition, the Shanxi government permits reduced coal production during the course of construction and production upgrades and we estimate the target coal mines of Pinglu Project will produce approximately 849,000 metric tons in 2011.”

About Puda Coal, Inc.

Puda Coal, through its subsidiaries, supplies premium high grade metallurgical coking coal used to produce coke for steel manufacturing in China. The Company currently possesses 3.5 million metric tons of annual coking coal capacity. The Company is in the process of adding coal mining operations to its business, as an acquirer and consolidator and acquirer of coal mines in Shanxi Province. On September 30, 2009, Shanxi Coal, a 90% indirect subsidiary of the Company, was appointed by the Shanxi provincial government as an acquirer and consolidator of eight thermal coal mines located Pinglu County in southern Shanxi Province. Shanxi Coal plans to consolidate the eight coal mines into five, increasing their total annual capacity from approximately 1.1 million to 3.6 million metric tons. Shanxi Coal received another approval by the Shanxi provincial government to consolidate four additional coking coal mines into one coal mine in Huozhou County. After the completion of the consolidation, the Jianhe project is expected to increase the total annual capacity from 720,000 metric tons to 900,000 metric tons, according to the Shanxi provincial government’s approval. For more information, please visit http://www.pudacoalinc.com.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. For example, our ability to acquire and consolidate the remaining target coal mines are subject to, among other things, the risks and uncertainties relating to the market and geological condition, due diligence, negotiation for definitive agreements, etc. which are beyond our control; our success in executing the strategy of entering coal mining sector will depend on our management‘s ability and capacity to execute our strategy and manage the coal mine operations. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

VisionChina Media (VISN) and Focus Media Announce the Purchase of VisionChina Media Common Shares

BEIJING, Dec. 30, 2010 /PRNewswire-Asia/ — VisionChina Media Inc. (“VisionChina Media”) (Nasdaq:VISN – News), one of China‘s largest out-of-home digital television advertising networks on mass transportation systems, and Focus Media Holding Limited (“Focus Media”) (Nasdaq:FMCN – News), China‘s largest lifestyle community digital out-of-home media company, today announced they have entered into a securities purchase agreement, pursuant to which Focus Media will purchase 15,331,305 newly issued common shares of VisionChina Media at a price of US$3.979 per share, equivalent to US$3.979 per ADS, for a total consideration of approximately US$61.0 million.

JJ Media Investment Holding Limited (“JJ Media”), an entity owned by Jason Nanchun Jiang, the chairman and chief executive officer of Focus Media and one of Focus Media’s largest shareholders, and Front Lead Investments Limited (“Front Lead”), an entity beneficially owned by Limin Li, the chief executive officer and largest shareholder of VisionChina Media (together the “Investors”) will each also acquire 1,022,087 newly issued common shares of VisionChina Media at the price of US$3.979 per share, equivalent to US$3.979 per ADS, each for a consideration of approximately US$4.0 million.

The transaction is subject to customary closing conditions and is expected to be completed in early January 2011.  Each of Focus Media and the Investors will pay 80% of the consideration and deliver a promissory note in the amount of the remaining 20% of the consideration to VisionChina Media at closing.  The payment under the promissory notes will be due on March 31, 2011.

Following the transaction, Front Lead, an entity beneficially owned by Limin Li, will remain VisionChina Media’s largest shareholder with 17.2% of VisionChina Media’s outstanding issued shares.  Focus Media will hold approximately 15%, and JJ Media will hold 1%, of VisionChina Media’s outstanding issued shares respectively.  Focus Media, the Investors and VisionChina Media will also enter into a Shareholders Agreement, pursuant to which Focus Media is entitled to nominate one designee to VisionChina Media’s board of directors following the transaction.  In addition, Focus Media, the Investors and VisionChina Media will also enter into a Registration Rights Agreement, pursuant to which Focus Media and the Investors will hold certain registration rights.

“We are very pleased that Focus Media, China‘s largest lifestyle community out-of-home digital media company is investing in VisionChina Media.  The purchase of this substantial block of our outstanding shares demonstrates that Focus Media recognizes that we have complementary businesses.  Both companies see the future of out-of-home digital mobile television in China, and are confident in our leadership in our respective industry segments.  We hope this alignment will provide a base from which to consider future business opportunities of mutual interest.” said Mr. Limin Li, founder, Chairman and chief executive officer of VisionChina Media.

Mr. Jiang, founder, Chairman and chief executive offer of Focus Media commented, “This is an opportunity for our company to partner with a proven market leader in the mobile television networks advertising business.  VisionChina Media’s mass transportation mobile television network and Focus Media’s office, residential, hypermarket and supermarket television networks and theater network are highly complementary to each other, which we believe will offer opportunities to bring integrated media solutions and greater media value to advertisers.  This minority investment in VisionChina Media is very much in line with Focus Media’s established development strategy of focusing on growing and investing in our core businesses while reducing our non-core businesses, and does not indicate any change in our existing stated direction.  I am very pleased to be purchasing a 1% stake in VisionChina Media as a reflection of my confidence in the prospects for cooperation between VisionChina Media and Focus Media.”

ABOUT VISIONCHINA MEDIA INC.

VisionChina Media Inc. (Nasdaq:VISN – News) operates an out-of-home advertising network on mass transportation systems, including buses and subways. As of September 30, 2010, VisionChina Media Inc.’s advertising network included 128,139 digital television displays on mass transportation systems in 23 of China‘s economically prosperous cities, including Beijing, Shanghai, Guangzhou and Shenzhen.  VisionChina Media Inc. has the ability to deliver real-time, location-specific broadcasting, including news, stock quotes, weather and traffic reports and other entertainment programming.  For more information, please visit http://www.visionchina.cn.

ABOUT FOCUS MEDIA HOLDING LIMITED

Focus Media Holding Limited (Nasdaq:FMCN – News) operates China‘s largest lifestyle community media network, tracking the lifestyle of the consumers and using its media advertising platforms for residential communities, office buildings, shopping malls and movie theaters.  Through its multi-platform digital media platforms, as of September 30, 2010, Focus Media’s digital out-of-home advertising network had approximately 196,000 LCD displays and approximately 312,000 advertising in-elevator poster and digital frames, installed in 184 cities throughout China, with a daily coverage of more than 170 million mainstream urban residents.  For more information about Focus Media, please visit our website at http://ir.focusmedia.cn.

SAFE HARBOR: FORWARD-LOOKING STATEMENTS

This announcement contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995.  These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements, but the absence of these words does not mean that a statement is not forward-looking.  Among other things, quotations from Limin Li and Jason Nanchun Jiang in this press release contain forward-looking statements.  Forward-looking statements involve inherent risks and uncertainties.  A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.  Neither VisionChina Media nor Focus Media undertakes any obligation to update any forward-looking statement, except as required under applicable law.

This press release is provided for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities.  Securities may not be offered or sold in the United States absent registration or an exemption from registration.  Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the issuer or selling security holder and that will contain detailed information about the company and management, as well as financial statements.

AirMedia (AMCN) Renews its Concession Rights Contract with China Eastern Airlines for Ten Years

BEIJING, Dec. 30, 2010 /PRNewswire-Asia-FirstCall/ — AirMedia Group Inc. (“AirMedia”) (Nasdaq:AMCN – News), a leading operator of out-of-home advertising platforms in China targeting mid-to-high-end consumers, today announced that it recently renewed its concession rights contract with China Eastern Airlines to operate digital TV screens on its airplanes on an exclusive basis for ten years until December 31, 2020.

“China Eastern Airlines is one of the top three airlines in China. Our successful renewal with China Eastern Airlines further secures our concession rights with major airlines for the long term. Following our recent renewals of concession rights contracts with Terminal 3 of the Beijing airport and China Southern Airlines, each for five years, we notice that airports and airlines now become willing to commit to longer-term contracts with their trusted business partners. As a leading air travel advertising platform operator, AirMedia will benefit from this development,” remarked Herman Guo, chairman and chief executive officer of AirMedia.

About AirMedia Group Inc.

AirMedia Group Inc. (Nasdaq:AMCN – News) is a leading operator of out-of-home advertising platforms in China targeting mid-to-high-end consumers. AirMedia operates the largest digital media network in China dedicated to air travel advertising. AirMedia operates digital frames in 34 major airports, including the 15 largest airports in China. AirMedia also operates digital TV screens in 38 major airports, including 26 out of the 30 largest airports in China. In addition, AirMedia sells advertisements on the routes operated by nine airlines, including the four largest airlines in China. In selected major airports, AirMedia also operates traditional media platforms, such as billboards and light boxes, and other digital media, such as mega LED screens.

In addition, AirMedia has obtained exclusive contractual concession rights until the end of 2014 to develop and operate outdoor advertising platforms at Sinopec’s service stations located throughout China.

For more information about AirMedia, please visit http://www.airmedia.net.cn.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expect,” “anticipate,” “future,” “intend,” “plan,” “believe,” “estimate,” “confident” and similar statements. Among other things, the quotations from management in this announcement, as well as AirMedia’s strategic and operational plans, contain forward-looking statements. AirMedia may also make written or oral forward-looking statements in its reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about AirMedia’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to: if advertisers or the viewing public do not accept, or lose interest in, our air travel advertising network, we may be unable to generate sufficient cash flow from our operating activities and our prospects and results of operations could be negatively affected; we derive most of our revenues from the provision of air travel advertising services, and any slowdown in the air travel advertising industry in China may materially and adversely affect our revenues and results of operations; our strategy of expanding our advertising network by building new air travel media platforms and expanding into traditional media in airports may not succeed, and our failure to do so could materially reduce the attractiveness of our network and harm our business, reputation and results of operations; if we do not succeed in our expansion into gas station and other outdoor media advertising, our future results of operations and growth prospects may be materially and adversely affected; if our customers reduce their advertising spending or are unable to pay us in full, in part or at all for a period of time due to an economic downturn in China and/or elsewhere or for any other reason, our revenues and results of operations may be materially and adversely affected; we face risks related to health epidemics, which could materially and adversely affect air travel and result in reduced demand for our advertising services or disrupt our operations; if we are unable to retain existing concession rights contracts or obtain new concession rights contracts on commercially advantageous terms that allow us to operate our advertising platforms, we may be unable to maintain or expand our network coverage and our business and prospects may be harmed; a significant portion of our revenues has been derived from the five largest airports and three largest airlines in China, and if any of these airports or airlines experiences a material business disruption, our ability to generate revenues and our results of operations would be materially and adversely affected; our limited operating history makes it difficult to evaluate our future prospects and results of operations; and other risks outlined in AirMedia’s filings with the U.S. Securities and Exchange Commission. AirMedia does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Radient Pharmaceuticals (RPC) Signs Distribution Agreement With Hong Kong Based Bio-Asia Diagnostics Co. Ltd.

TUSTIN, CA — (Marketwire) — 12/29/10 — Through its subsidiary AMDL Diagnostics Inc., Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic cancer tests, announced today it has signed a full-service five-year exclusive distribution agreement with Hong Kong based Bio-Asia Diagnostics Co. Ltd. (Bio-Asia). The signing of this distribution agreement will enable RPC to bring its Onko-Sure™ IVD cancer test into the Hong Kong healthcare market. The agreement also grants Bio-Asia non-exclusive rights to distribute Onko-Sure®, for research use only (“RUO”), in the People’s Republic of China (“PRC”).

Under the terms, Bio-Asia has committed to purchase a minimum of 800 Onko-Sure® test kits over the duration of the agreement. As a full service distributor, Bio-Asia will provide marketing, sales, and distribution services to get Onko-Sure in major diagnostic centers, clinical reference labs, and hospitals in Hong Kong. Additionally, Bio-Asia will reach out to hospitals and cancer research centers in the PRC to provide Onko-Sure® test kits for RUO purposes. Bio-Asia has a network of over 300 major hospitals in Hong Kong and the PRC.

RPC’s Chairman and CEO Douglas MacLellan commented, “This announcement represents a strategic advancement in the global commercialization of our Onko-Sure® cancer test. Hong Kong provides an excellent market for diagnostic tests and Bio-Asia is a leading distribution company there as well as in the PRC. Support from international distributors, including Bio-Asia, is key to the long-term growth of Radient and we are excited to add them to our growing list of distribution partners. Through such partnerships RPC is making substantial progress in meeting global demand for cancer testing.”

MacLellan continued, “Beginning 2011, committed minimums for Hong Kong plus RUO sales in the PRC are anticipated to generate over $200,000 USD annually. We appreciate the confidence Bio-Asia has demonstrated in RPC and we will support their efforts to continue to aggressively expand distribution throughout this important territory.”

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

About Bio-Asia Diagnostics:
Bio-Asia Diagnostics Company Ltd. was founded in Hong Kong in 1996 to represent a number of world-leading manufacturers to channel their top quality diagnostic products to the region. Bio-Asia distributes products and provides services for various international diagnostics and healthcare products manufacturers. Building on distribution and sales to hospitals in Asia, Bio-Asia has become a leading diagnostics distribution company, providing a wide range of medical diagnostic solutions to hospitals and clinics to meet rapidly growing demand in the region. In addition to operations in Hong Kong, Bio-Asia has four branches in China located in Beijing, Shanghai, Guangzhou and Fuzhou.

Bio-Asia Diagnostics has built up a network of more than 300 major hospitals that are all repeat customers in China and Hong Kong. Bio-Asia currently represents a number of world-leading manufacturers to channel their top quality diagnostic products to the region. Among the globally famous brands are Grifols, Interlab, i-STAT, Bayer Diagnostics, Abbott, Cholestech, Standard Diagnostics, and Data Innovations. Visit www.bio-asia.com for more information.

RPC Contact Information:
For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or send e-mail to info@radient-pharma.com. For Investor Relations contact Kristine Szarkowitz at IR@RadientPharma.com or 1.206.310.5323.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Add to Digg Bookmark with del.icio.us Add to Newsvine

RPC Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
(Tel : ) 206.310.5323

GenVec (GNVC) Forms Collaboration With World-Leading Animal Health Company

GAITHERSBURG, Md., Dec. 29, 2010 /PRNewswire/ — GenVec, Inc. (Nasdaq: GNVC) today announced that the company will be working with Merial to develop and commercialize GenVec’s proprietary vaccine technology for use against foot-and-mouth disease (FMD). Merial is the leading FMD vaccine producer in the world, with leading positions in all key markets. Under the agreement, Merial will be responsible for all costs related to the development and commercialization of FMD vaccines developed through the collaboration.  GenVec will receive development milestones and royalties on sales.

GenVec’s novel FMD vaccine approach utilizes GenVec’s proprietary adenovector technology and is manufactured on a proprietary GenVec cell line that is capable of producing antigens without the use of the highly contagious FMD virus. Because the vaccine is produced without using live or killed virus materials, it can be produced cost effectively in the US and around the world.

“We look forward to working with GenVec to explore this promising technology for FMD vaccines,” said Teshome Mebatsion, Senior Director Vector Vaccine Research, Merial.  Robert Nordgren, Global Head of Merial’s Bio R&D added that “Merial sees great potential for GenVec’s technology to positively impact the way that animal vaccines are produced and developed.”

“Our relationship with Merial complements our strategy of entering into collaborations to support the development of our pipeline of products,” said Dr. Paul Fischer, GenVec’s President and Chief Executive Officer.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec uses proprietary drug discovery and development technologies to support a portfolio of product programs that address the prevention and treatment of a number of major diseases.  In collaboration with Novartis, GenVec is developing novel treatments for hearing loss and balance disorders. GenVec also develops and is evaluating the potential of TNFerade for the treatment of certain cancers and is developing vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the Company’s various filings with the Securities and Exchange Commission.

About Merial

Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,600 people and operates in more than 150 countries worldwide. Its 2009 sales were $2.6 billion. Merial is the Animal Health subsidiary of sanofi-aventis.

For more information, please see www.merial.com.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec’s product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec’s proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec’s business, financial conditions and results of operations, are contained in GenVec’s filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

BASi (BASI) Announces Partnership With Pharmasset

WEST LAFAYETTE, IN–(Marketwire – 12/29/10) – BASi (Bioanalytical Systems, Inc.) (NASDAQ:BASI – News), a life sciences company in the Purdue Research Park, has entered into a Preferred Provider Agreement (PPA) with Princeton, New Jersey-based Pharmasset Inc. (NASDAQ:VRUS – News), a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, to provide preclinical services for pre-IND and post-IND activities. The agreement includes provisions to provide exclusive toxicology services as well as pharmaceutical analysis and bioanalytical services as needed.

BASi President and Chief Executive Officer, Anthony S. Chilton, Ph.D., stated, “The agreement between Pharmasset and BASi is an important strategy and commitment for both companies. It represents a significant step in BASi’s strategy to work closely with our partners in the pharmaceutical industry. We look forward to developing our relationship and continuing to contribute to the successful development of Pharmasset’s future medicines.”

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset’s primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir™ for the treatment of human immunodeficiency virus (HIV). Research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. Pharmasset currently has four clinical-stage product candidates. RG7128 is in two Phase 2b clinical studies in combination with Pegasys® plus Copegus® and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Other clinical stage HCV candidates include PSI-7977, an unpartnered nucleotide analog that has recently initiated 12 weeks of dosing in a Phase 2b study, and PSI-938, an unpartnered nucleotide analog in a Phase 1 study. Pharmasset also has in its pipeline an additional purine nucleotide analog, PSI-661, in advanced preclinical development. Racivir, for the treatment of HIV, has completed a Phase 2 clinical study.

Pegasys® and Copegus® are registered trademarks of Roche.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research services and research instruments and supplies to the world’s leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASInc.com for more about BASi.

This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company’s filings with the Securities and Exchange Commission.

Uranerz (UZR) Completes $20 Million Financing

CASPER, WYOMING–(Marketwire – 12/29/10) – Uranerz Energy Corporation (“Uranerz” or the “Company”) (TSX:URZ – News) (AMEX:UZR – News) (Frankfurt:U9E – News) is pleased to announce that it has completed its “at-the-market” financing and has raised US$20 million in gross proceeds through Haywood Securities (USA) Inc., acting as agent.

Uranerz Energy Corporation now has approximately $36 million in its treasury, and there are 70,781,433 shares issued and outstanding. The Company is well-positioned in anticipation of receipt of the required licenses and permits to begin construction of the Nichols Ranch ISR Uranium Project.

About Uranerz

Uranerz Energy Corporation is a U.S.-based uranium company focused on achieving near-term commercial in-situ recovery (“ISR”) uranium production in Wyoming, the largest producer of uranium of any U.S. state. The Uranerz management team has specialized expertise in the ISR uranium mining method, and has a record of licensing, constructing and operating commercial ISR uranium projects.

Uranerz Energy Corporation is listed on the NYSE Amex and the Toronto Stock Exchange under the symbol “URZ,” and listed on the Frankfurt Stock Exchange under the symbol “U9E.”

Further Information

For further information, please contact Derek Iwanaka, Manager of Investor Relations at 1-800-689-1659 or by email at info@uranerz.com. Alternatively, please refer to the Company’s website at www.uranerz.com, review the Company’s filings with the SEC at www.sec.gov or visit the Company’s profile on SEDAR at www.sedar.com.

Forward-looking Statements

This press release may contain or refer to “forward-looking information” and “forward-looking statements” within the meaning of applicable United States and Canadian securities laws, which may include, but are not limited to, statements with respect to the Company’s anticipation that it will receive permits and licenses to begin construction of the Nichols Ranch ISR Uranium Project, anticipated use of proceeds, future production, planned development, capital, the availability of future financing for exploration or development, the regulatory approval of planned operations, and other plans, estimates and expectations. Such forward-looking statements reflect the Company’s current views with respect to future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties outlined in the Company’s most recent financial statements and reports and registration statement filed with the SEC (available at www.sec.gov) and with Canadian securities regulators (available at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. We do not undertake to update forward-looking information or forward-looking statements, except as required by law.

Cavico (CAVO) Awarded $6 Million Construction Contract for Song Bung 2 Hydropower Plant

HANOI, Vietnam, Dec. 28, 2010 (GLOBE NEWSWIRE) — Cavico Corp. (Nasdaq:CAVO) (“Cavico” or the “Company”), a major infrastructure construction, infrastructure investment, and natural resources conglomerate based in Vietnam, today announced that its subsidiary, Cavico Bridge and Tunnel, has signed a construction contract with Electricity of Vietnam (“EVN”), a state-owned electricity company, for the Song Bung 2 Hydropower project.

The contract is valued at $6 million and includes cost escalation clauses that may increase the revenues associated with the project. Under the terms of the contract, Cavico will be responsible for the construction of three tunnels, a surge tank, and a power house. Cavico expects to complete construction by 2014.

The Song Bung 2 Hydropower project, which is included in Vietnam’s national power development plan approved by the prime minister’s office, is located on the Vu Gia-Thu Bon River in Lae village, Quang Nam Province. With a total planned capital investment of $183 million, the Song Bung 2 hydropower plant will have a 100-megawatt capacity, providing 426 million kilowatt-hours of energy annually upon completion.

“Cavico is delighted to be awarded this construction contract for the Song Bung 2 Hydropower project,” commented Mr. Hai Thanh Tran, vice president of Cavico. “Our team and equipment are ready to be deployed to the site, and we anticipate a smooth transition into the construction process, which we expect to complete within the agreed time frame.”

The Company also wishes to correct a statement made in its press release issued Monday, December 27, 2010. The corrected statement should read as follows: “The headrace tunnel is 7 miles long and 16 feet wide and is considered the longest and most sophisticated tunnel to be constructed in Vietnam.”

About Cavico Corp.

Cavico Corp. is focused on large infrastructure projects, which include the construction of hydropower facilities, dams, bridges, tunnels, roads, mines and urban buildings. Cavico is also making investments in hydropower facilities, cement production plants, mineral exploration and urban developments in Vietnam.  The company employs more than 3,000 employees on projects worldwide, with offices throughout Vietnam and a satellite office in Australia. The Company now has three subsidiaries, Cavico Mining (HSX:MCV), Cavico Industry & Mineral (HNX:CMI), and Cavico Construction Manpower & Services (HNX:CMS), which are listed in Vietnam on the Ho Chi Minh and Hanoi Stock Exchanges.

Founded in 2000, Cavico is a major infrastructure construction, infrastructure investment and natural resources conglomerate headquartered in Hanoi, Vietnam. Cavico is highly respected for its core competency in the construction of mission-critical infrastructure including hydroelectric plants, highways, bridges, tunnels, ports and urban community developments. One of the Company’s primary competitive advantages is its ability to nurture a project “from concept through completion” with a vertical portfolio of interrelated investment, permitting, design, construction management and facility maintenance services. Cavico’s project partners include top multi-national corporations and government organizations. The Company employs more than 3,000 full-time, part-time, and seasonal workers. For more information, visit http://www.cavicocorp.com. Information on the Company’s Web site or any other Web site does not constitute a portion of this release.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Company’s ability to obtain the necessary financing to continue and expand operations, to market its construction services in new markets and to offer construction services at competitive pricing, the Company’s ability to complete projects in the time frame specified; anticipated revenue from the projects to attract and retain management, and to integrate and maintain technical information and management information systems; the effects of currency policies and fluctuations, general economic conditions and other factors detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission and other regulatory authorities. These statements include, without limitation, statements regarding our ability to prepare the Company for growth; the Company’s planned expansions, and predictions and guidance relating to the Company’s future financial performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:  Cavico Corp.
          Timothy Pham, Vice President and Director
          +1-714-843-5456
          cavicohq@cavico.us

          RedChip Companies, Inc.
          Investor Relations Contact:
          Dave Gentry
          800-733-2447, Ext. 104
          407-644-4256, Ext. 104
          info@redchip.com

China TransInfo (CTFO) Announces RMB 6.2 Million Contract for Beijing Traffic-Information Service

Sinovac (SVA) Receives SFDA Approval to Commence Clinical Trials for Inactivated Enterovirus Type 71 Vaccine

Ditech Networks (DITC) Names Ken Naumann as Vice President Worldwide Sales

Dec. 23, 2010 (Business Wire) — Ditech Networks, Inc. (NASDAQ:DITC), a leader in voice processing systems, announced today that Ken Naumann has been named Vice President of Worldwide Sales. Naumann will lead sales efforts for both VQA™ and PhoneTag products worldwide.

“We are excited to have Ken on board at Ditech. Both his experience in sales management, and his knowledge of complex software based transactions and managed services will be of great benefit to us,” said Todd Simpson, Ditech Networks President and CEO. “We look forward to Ken contributing to all aspects of our sales processes, and to the long term success of the company.”

Naumann has extensive executive and sales leadership experience. He has lead large worldwide field organizations for multiple enterprise software companies such as Guidance Software (NASD: GUID) and BindView Development (NASD: BVEW). As Vice President of WW Sales at Guidance Software, Naumann doubled revenue over a two year period. During his 10 years tenure at BindView, Naumann held a variety of executive management roles including Vice President of the Americas and Vice President of WW Sales as the company grew from a start up into $88M publicly traded company. “I am very pleased to be joining Ditech Networks,” said Naumann. “The company has excellent products, and I look forward to pushing Ditech aggressively in the marketplace.”

In connection with Mr. Naumann’s appointment, Mr. Naumann was granted an option to purchase 140,000 shares of Ditech common stock with an exercise price equal to the fair market value of Ditech’s common stock on the date of grant, and restricted stock units for 20,000 shares of Ditech common stock, both of which vest over four years, as an inducement to join Ditech. At the same time, a new non-officer employee of Ditech was granted an option to purchase 7,000 shares of Ditech common stock with the same terms, as an inducement to join Ditech.

About Ditech Networks

Ditech Networks is revolutionizing modern communications with advanced voice processing solutions that perform tasks spanning from voice-enabled Web 2.0 and unified communications services to voice quality enhancement. Ditech believes in the power and simplicity of human speech; its solutions deliver high-quality voice communication and will enable compelling voice capabilities to new communications methods like social networking and text messaging, allowing consumers to use voice in ways that make sense in today’s Web 2.0-savvy world.

Leveraging over 20 years of deployments with communications providers around the world, Ditech’s products help global communications companies meet the multiple challenges of service differentiation, network expansion and call capacity, by delivering consistent, dependable voice quality. Ditech’s customers include Verizon, Sprint/Nextel, Orascom Telecom, AT&T, Telus, Global Crossing and West Corporation. Ditech Networks is headquartered in Mountain View, California.

Ditech Networks, Inc.

Bill Tamblyn, 650-623-1309 (Investors)

Karl Brown, 650-623-1346 (General)

Magnum Hunter Resources (MHR) Provides Marcellus Shale Development Activity Update

HOUSTON, TX — (Marketwire) — 12/23/10 — Magnum Hunter Resources Corporation (NYSE Amex: MHR) (NYSE Amex: MHR-PC) (“Magnum Hunter,” or the “Company”) is providing today a horizontal drilling update on its upstream operations and a status report on its midstream activities in the Marcellus Shale resource play located across approximately 50,000 net mineral acres located in northwestern West Virginia and southeastern Ohio.

Marcellus Shale Drilling Update

The Company’s first well drilled in the natural gas liquids rich leg of the Marcellus Shale of northwestern West Virginia is the Weese Hunter #1001, located in Tyler County. Alpha Hunter Drilling, a wholly owned subsidiary of Magnum Hunter, spud the Weese Hunter #1001 in late July 2010 and reached vertical total depth of approximately 6,510 feet in mid August 2010. A third party drilling rig commenced the horizontal leg in mid September 2010 and reached a horizontal length of approximately 4,028 feet. Total measured depth for the Weese Hunter #1001 is approximately 10,388 feet. A twelve stage frac job was successfully completed in December. The Weese Hunter #1001 well recently tested at an initial production rate (“IP”) of 7.0 MMcfe per day with flowing tubing pressures of 2350 psi on a 22/64 inch choke. The British Thermal Unit (“BTU”) content of the well was measured at approximately 1,225. The Weese Hunter #1001 began producing yesterday into the recently completed Eureka Hunter pipeline system. The currently estimated economic ultimate recovery (“EUR”) for the Weese Hunter #1001 is estimated by the Company’s in-house reservoir engineers to be approximately 4 Bcfe. Magnum Hunter’s wholly-owned subsidiary, Triad Hunter, LLC, is the operator of this well and owns a 100% working interest with a 84.3% net revenue interest.

Eureka Hunter Midstream Update

The first phase of six miles of the 20 inch Eureka Hunter Pipeline system was purged yesterday and turned to sales into Dominion Transmission’s TL-265 line. The second and third phases of this new system will commence construction in early 2011 as part of the Company’s capital budget program for next year. When operational, the recently ordered 200 MMCFD cryogenic natural gas processing plant will allow efficient processing of natural gas liquids from Company owned production as well as natural gas volumes gathered from third parties in this region.

Marcellus Shale 2010 Capex Update

The Company’s total capital expenditure budget allocation for drilling, completion, leasing, and pipeline construction operating activities for the Marcellus Shale in fiscal year 2010 remains at approximately $18 million, representing 32% of Magnum Hunter’s total fiscal year 2010 capital budget of an estimated $55 million. Through October 31, 2010, the Company has spent approximately $16.6 million of the $18 million budget allocation for this business segment.

Management Comments

James W. Denny, President of Triad Hunter, LLC., a wholly owned subsidiary of Magnum Hunter Resources Corporation, commented, “We are excited to have our first horizontal Marcellus well on production at rates that are at the high end of our original expectations. The downhole well log characteristics of our next two horizontal wells that have been drilled and are waiting on fracture stimulation, have indicated similar characteristics. We had a competitive edge by having detailed well information from thirty-one previously drilled vertical Marcellus wells by Triad Hunter prior to completing the acquisition of this Company earlier this year. Since none of our new Marcellus Shale horizontal drilling locations on our existing acreage position are currently booked as proved reserves, the anticipated reserve additions from these recent activities should add significant value in the future to our shareholders. We have currently budgeted a minimum of twelve wells for drilling in fiscal year 2011 for this region. Additionally, the high BTU nature of the production from this portion of the Marcellus Shale in our area of operations will allow us to maximize the liquids rich nature of this gas stream because of our midstream commitments in gathering, transmission, and processing.”

About Magnum Hunter Resources Corporation

Magnum Hunter Resources Corporation and subsidiaries are a Houston, Texas based independent exploration and production company engaged in the acquisition of exploratory leases and producing properties, secondary enhanced oil recovery projects, exploratory drilling, and production of oil and natural gas in the United States. The Company is presently active in three of the “big five” emerging shale plays in the United States.

For more information, please view our website at http://www.magnumhunterresources.com/

Forward-Looking Statements

This press release contains statements concerning Magnum Hunter Resources Corporation’s expectations, beliefs, plans, intentions, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are not historical facts. These statements and others contained in this presentation that are not historical are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the Private Securities Litigation Reform Act of 1995 (the “Litigation Reform Act”). Actual results may differ materially from those expressed or implied by these statements. You can generally identify our forward-looking statements by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “objective,” “plan,” “potential,” “predict,” “projection,” “should,” “will,” or other similar words. Such forward-looking statements relate to, among other things: (1) the Company’s proposed exploration and drilling operations on its various properties, (2) the expected production and revenue from its various properties, (3) the Company’s proposed redirection as an operator of certain properties and (4) estimates regarding the reserve potential of its various properties. These statements are qualified by important factors that could cause the Company’s actual results to differ materially from those reflected by the forward-looking statements. Such factors include but are not limited to: (1) the Company’s ability to finance the continued exploration, drilling and operation of its various properties, (2) positive confirmation of the reserves, production and operating expenses associated with its various properties, (3) the general risks associated with oil and gas exploration, development and operations, including those risks and factors described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including but not limited to the Company’s Annual Report on Form 10-K for the period ended December 31, 2009 filed on March 31, 2010, and the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2010, June 30, 2010 and September 30, 2010 and, filed on May 17, 2010, August 12,2010 and November 12, 2010, respectively. Magnum Hunter Resources Corporation cautions readers not to place undue reliance on any forward-looking statements. Magnum Hunter Resources Corporation does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Magnum Hunter Contact:
M. Bradley Davis
Senior Vice President of Capital Markets
bdavis@magnumhunterresources.com
(832) 203-4545

Alexco (AXU) Announces Closing of CAD$41,000,000 Bought Deal Financing

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 12/23/10 — Alexco Resource Corp. (TSX: AXR)(NYSE Amex: AXU) (“Alexco” or the “Company”) is pleased to announce that it has closed the bought deal equity financing announced December 7, 2010 (the “Offering”). The Company has issued 5,000,000 common shares at a price of CAD$8.20 per common share for gross proceeds of CAD$41,000,000.

The Offering was led a syndicate of underwriters (the “Underwriters”). The Underwriters received a cash commission of 6% of the gross proceeds raised through the Offering and warrants (“Broker Warrants”) equal in number to 4% of the number of common shares issued through the Offering. Each Broker Warrant shall be exercisable to acquire one common share of the Company at an exercise price of CAD$8.50 for a period of 12 months from closing.

The Company intends to use the net proceeds of the Offering to fund project development and ongoing exploration activities, and for general working capital.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Common Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Common Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

About Alexco

Alexco’s business is to unlock value and manage risk at mature, closed or abandoned mine sites through integration and implementation of the Company’s core competencies which include management of environmental services, execution of mine reclamation and closure operations and if appropriate, rejuvenation of exploration and development of new mining opportunities.

Some statements in this news release contain forward-looking information concerning the Company’s intended use of proceeds, anticipated results and developments in the Company’s operations in future periods, planned exploration and development of its properties, plans related to its business or financings and other matters that may occur in the future, made as of the date of this press release. Forward-looking statements may include, but are not limited to, statements with respect to future remediation and reclamation activities, future mineral exploration, the estimation of mineral reserves and mineral resources, the realization of mineral reserve and mineral resource estimates, the timing of activities and the amount of estimated revenues and expenses, the success of exploration activities, permitting time lines, requirements for additional capital and sources and uses of funds. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements. Such factors include, among others, risks related to actual results of remediation and reclamation activities; actual results of exploration activities; conclusions of economic evaluations; changes in project parameters as plans continue to be refined; future prices of gold, silver and other commodities; possible variations in ore bodies, grade or recovery rates; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the mining industry; and delays in obtaining governmental approvals or financing or in the completion of development activities.

Contacts:
Alexco Resource Corp.
Clynton R. Nauman
President and Chief Executive Officer
604-633-4888
604-633-4887 (FAX)
info@alexcoresource.com
www.alexcoresource.com